2 news items
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
MRVI
18 Apr 24
to ensuring the safety and efficacy of this new class of medicines for patients."
Company and site leadership
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
MRVI
22 Feb 24
." Martin continued, "Maravai remains focused on expanding our product portfolio, advancing our market leadership in the mRNA space
- Prev
- 1
- Next